Using a relatively untested technology to indigenously develop its swine flu vaccine will cost Cadila Pharmaceuticals precious time.
Cadila, which is developing the Influenza A HINI (swine flu) vaccine in collaboration with US-based Novavax, is yet to get the government’s nod for clinical trials.
“We have not given approval (for clinical trials) yet as they are using a new technology called ‘virus like particles’ (VLP),” Drug Controller General of India Surinder Singh said.
“We are still studying the process... And it would take some more time before we decide on that.”
Last year, Ahmedabad-based Cadila and four other Indian companies — Zydus Cadila, Bharat Biotech, Panacea Biotech and Serum Institute — had applied for the health regulator’s permission to conduct trials for vaccines in India.
The other firms got the permission and have started clinical trials for the vaccine.
Singh said globally there is only one vaccine that uses VLP technology. So, the company needs to substantiate the new technology’s credentials.
An email query sent to Cadila remained unanswered.